^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET Study” Ensayo fase III de trastuzumab + ALpelisib con o sin fulvestrant frente a trastuzumab + quimioterapia en pacientes con cáncer de mama avanzado HER2+ con mutación de PIK3CA y tratados previamente. “Estudio ALPHABET”

    Excerpt:
    ...4.Patients with a PIK3CA tumor mutation at central laboratory determination, preferably on the most recent available FFPE tumor sample. ...
    Trial ID:
    2020-005639-65
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Oncol
    Title:

    The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer

    Published date:
    06/15/2023
    Excerpt:
    The HCC1954 and KPL4 cells were exposed to alpelisib or to alpelisib + trastuzumab to generate derivatives with acquired resistance to alpelisib (AR) and to alpelisib + trastuzumab (ATR)….Alpelisib treatment resulted in dose-dependent inhibition of the growth of cells and enhanced the antitumor efficacy of anti-HER2 therapies in vitro. Alpelisib delayed tumor growth of HCC1954 xenografts in vivo....Our findings support the use of alfa-selective PI3K inhibitor to overcome therapeutic limitations associated with HER2 blockade in PIK3CA-mutant HER2+ BC.
    DOI:
    10.3389/fonc.2023.1108242